Real-world healthcare resource utilization and costs of weekly versus every-2-week cetuximab in metastatic colorectal cancer.
Conclusion: HRU was lower and HC were similar between the Q2W and Q1W regimens.
PMID: 33502247 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Erbitux | General Medicine | Healthcare Costs | Study